<DOC>
	<DOCNO>NCT01418963</DOCNO>
	<brief_summary>This two-part , randomize , double-blind , placebo-controlled study ass safety , pharmacokinetics pharmacodynamics single multiple ascend oral dos RO5285119 healthy volunteer . Anticipated time study 9 week subject .</brief_summary>
	<brief_title>A Study RO5285119 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male adult , 18 45 year age ( Part 1 ) healthy male female adult , 18 65 year age ( Part 2 ) Body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive Female subject must surgically sterile postmenopausal Male subject must use barrier method contraception duration study three month last dosing History presence significant disease disorder Positive hepatitis B. hepatitis C HIV infection History drug alcohol abuse suspicion regular consumption drug abuse Participation investigational drug device study within 3 month prior first dose Donation blood within 3 month prior first dose Regular smoker ( &gt; 5 cigarette , &gt; 3 pipefulls , &gt; 3 cigar per day ) History hypersensitivity allergic reaction Part 2 : Contraindications MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>